Prostatic specific antigen for prostate cancer screening: Going further or time over

Zhou Zhansong
DOI: https://doi.org/10.16016/j.1000-5404.2013.15.020
2013-01-01
Abstract:Prostate cancer is a popular malignant tumor in old males.Serum prostatic specific antigen(PSA) testing and digital rectal examination(DRE) have been considered the accepted method to screen prostate cancer in early stage.However,an elevated serum level of PSA can be caused not only by prostate cancer,but also by some benign prostate diseases,such as benign prostatic hyperplasia and prostatitis.Furthermore,a low level of PSA cannot exclude prostate cancer completely.In 2009,the middle-time results of two largestscale clinical trials(PLCO and ERSPC) in the world provided controversial conclusions of PSA for prostate cancer screening.From then on,the debates on PSA testing have been continued.Although the final conclusion is still unclear,it provides an opportunity to rescan the significance of PSA test.
What problem does this paper attempt to address?